Trials / Completed
CompletedNCT00363545
To Assess Immunogenicity, Reactogenicity & Safety of 2 Formulations of GSK's HRV Vaccine as 2-dose Vaccination (Infants)
A Study to Assess the Immunogenicity, Reactogenicity and Safety of 2 Different Formulations of GSK Biologicals' Live Attenuated HRV Vaccine, Given as a Two-dose Primary Vaccination, in Healthy Infants Previously Uninfected With HRV
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,274 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 6 Weeks – 12 Weeks
- Healthy volunteers
- Accepted
Summary
This trial will be conducted to evaluate the immunogenicity, reactogenicity and safety of the liquid formulation of GSK Biologicals' HRV vaccine compared to the lyophilized formulation of GSK Biologicals' HRV vaccine
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Lyophilized formulation of HRV vaccine | Lyophilized formulation of HRV vaccine |
| BIOLOGICAL | Liquid formulation of HRV vaccine | Liquid formulation of HRV vaccine |
Timeline
- Start date
- 2006-09-01
- Primary completion
- 2007-04-12
- Completion
- 2007-04-12
- First posted
- 2006-08-15
- Last updated
- 2018-06-08
- Results posted
- 2017-02-23
Locations
3 sites across 1 country: Panama
Source: ClinicalTrials.gov record NCT00363545. Inclusion in this directory is not an endorsement.